ANI Pharmaceuticals Stock Earnings Reports
ANI Pharmaceuticals Earnings Calls
Release date | May 09, 2025 |
EPS estimate | $1.37 |
EPS actual | $1.70 |
EPS Surprise | 24.09% |
Revenue estimate | 188.734M |
Revenue actual | 197.122M |
Revenue Surprise | 4.44% |
Release date | Feb 28, 2025 |
EPS estimate | $1.41 |
EPS actual | $1.63 |
EPS Surprise | 15.60% |
Revenue estimate | 169.962M |
Revenue actual | 190.574M |
Revenue Surprise | 12.13% |
Release date | Nov 08, 2024 |
EPS estimate | $1.09 |
EPS actual | $1.34 |
EPS Surprise | 22.94% |
Revenue estimate | 175.118M |
Revenue actual | 148.332M |
Revenue Surprise | -15.30% |
Release date | Aug 06, 2024 |
EPS estimate | $0.93 |
EPS actual | $1.02 |
EPS Surprise | 9.68% |
Revenue estimate | 129.05M |
Revenue actual | 138.04M |
Revenue Surprise | 6.97% |
Last 4 Quarters for ANI Pharmaceuticals
Below you can see how ANIP performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Release date | Aug 06, 2024 |
Fiscal end date | Jun 30, 2024 |
Price on release | $63.29 |
EPS estimate | $0.93 |
EPS actual | $1.02 |
EPS surprise | 9.68% |
Date | Price |
---|---|
Jul 31, 2024 | $65.72 |
Aug 01, 2024 | $63.85 |
Aug 02, 2024 | $61.01 |
Aug 05, 2024 | $59.16 |
Aug 06, 2024 | $63.29 |
Aug 07, 2024 | $57.01 |
Aug 08, 2024 | $56.43 |
Aug 09, 2024 | $57.90 |
Aug 12, 2024 | $59.68 |
4 days before | -3.70% |
4 days after | -5.70% |
On release day | -9.92% |
Change in period | -9.19% |
Release date | Nov 08, 2024 |
Fiscal end date | Sep 30, 2024 |
Price on release | $61.44 |
EPS estimate | $1.09 |
EPS actual | $1.34 |
EPS surprise | 22.94% |
Date | Price |
---|---|
Nov 04, 2024 | $56.01 |
Nov 05, 2024 | $57.31 |
Nov 06, 2024 | $58.40 |
Nov 07, 2024 | $58.38 |
Nov 08, 2024 | $61.44 |
Nov 11, 2024 | $61.74 |
Nov 12, 2024 | $61.00 |
Nov 13, 2024 | $59.83 |
Nov 14, 2024 | $58.91 |
4 days before | 9.69% |
4 days after | -4.12% |
On release day | 0.488% |
Change in period | 5.18% |
Release date | Feb 28, 2025 |
Fiscal end date | Dec 31, 2024 |
Price on release | $61.89 |
EPS estimate | $1.41 |
EPS actual | $1.63 |
EPS surprise | 15.60% |
Date | Price |
---|---|
Feb 24, 2025 | $55.57 |
Feb 25, 2025 | $54.51 |
Feb 26, 2025 | $55.01 |
Feb 27, 2025 | $54.58 |
Feb 28, 2025 | $61.89 |
Mar 03, 2025 | $58.46 |
Mar 04, 2025 | $59.13 |
Mar 05, 2025 | $59.68 |
Mar 06, 2025 | $61.05 |
4 days before | 11.37% |
4 days after | -1.36% |
On release day | -5.54% |
Change in period | 9.86% |
Release date | May 09, 2025 |
Fiscal end date | Mar 30, 2025 |
Price on release | $66.30 |
EPS estimate | $1.37 |
EPS actual | $1.70 |
EPS surprise | 24.09% |
Date | Price |
---|---|
May 05, 2025 | $72.56 |
May 06, 2025 | $70.27 |
May 07, 2025 | $70.82 |
May 08, 2025 | $71.53 |
May 09, 2025 | $66.30 |
4 days before | -8.63% |
4 days after | 0% |
On release day | 0% |
Change in period | -8.63% |
ANI Pharmaceuticals Earnings Call Transcript Summary of Q1 2025
Summary of ANI Pharmaceuticals Q1 2025 Earnings Call for Investors
1. Strong Financial Performance: ANI Pharmaceuticals reported record revenues of $197.1 million, up 43% year-over-year. Adjusted non-GAAP EBITDA was $50.7 million, and adjusted EPS increased to $1.70 compared to $1.21 in Q1 2024.
2. Updated Guidance for 2025:
- Total revenues projected to be between $768 million to $793 million, an increase from prior guidance of $756 million to $776 million.
- Adjusted non-GAAP EBITDA guidance raised to $195 million to $205 million from previous estimates of $190 million to $200 million.
- Cortrophin Gel revenues forecasted at $265 million to $274 million, reflecting growth of 34% to 38% year-over-year.
- ILUVIEN and YUTIQ revenues expected to be between $97 million to $103 million.
3. Cortrophin Gel Performance:
- Revenues grew to $52.9 million in Q1 2025, up 43% year-over-year.
- The product is experiencing strong growth across multiple specialties, particularly in rheumatology and ophthalmology, with a record number of new patients starting treatment.
- The introduction of a pre-filled syringe for Cortrophin is anticipated to improve convenience and might attract more prescribers.
4. Generics Business Growth:
- Generics revenues reached $98.7 million, a 41% increase YoY.
- Significant contributions from product launches, notably Prucalopride, have driven growth.
- ANI expects mid double-digit growth from the generics segment following a strong quarter.
5. Challenges in Retina Products:
- ILUVIEN and YUTIQ generated $16.1 million in Q1, with U.S. performance impacted by Medicare challenges and turnover in the sales force.
- Management is optimistic, noting positive trends in April and a commitment to improving market access through specialized pharmacy options and educational programs.
6. Tariff Situation:
- ANI is well positioned, with over 90% of revenue generated from products manufactured in the U.S., minimizing reliance on foreign imports, especially from China.
7. Management Insights:
- The team emphasized their commitment to expanding the Cortrophin franchise and managing challenges as they arise, while expressing confidence in their long-term strategies regarding all products.
8. Upcoming Obligations:
- ANI is preparing for an upcoming trial regarding a royalty action against CG Oncology, which is set for July 21, 2025.
Conclusion
ANI Pharmaceuticals reported a robust Q1 2025 and provided an optimistic outlook for the year, primarily driven by growth in Cortrophin Gel, the generics segment, and strategic plans to address challenges in their retina business. The management team remains focused on executing their growth strategy while maintaining a strong balance sheet. Investors should consider the positive revenue trends, the strategic initiatives in place, and potential market expansion when evaluating ANI's stock.